Mr. Francois-Karl Brouillette reports

NEPTUNE AND INGENUTRA SIGN AN EXCLUSIVE WORLDWIDE AGREEMENT FOR MAXSIMIL

Neptune Technologies & Bioressources Inc., through its wholly owned subsidiary, Biodroga Nutraceutical Inc., has signed an exclusive, worldwide and royalty-bearing commercial agreement with Ingenutra Inc. for its patented and clinically studied MaxSimil specialty ingredient. Designed as a unique delivery system, MaxSimil allows for enhanced bioavailability and absorption of lipid-based and lipid-soluble nutraceuticals ingredients such as omega-3 fish oils, vitamins A, D, K and E, CoQ10, and others.

The agreement allows Neptune to manufacture, distribute and sell MaxSimil in the nutraceutical field worldwide. The terms also cover potential collaboration between both companies on clinical trials. The agreement is valid until 2028 and supersedes a previous arrangement between Biodroga and Ingenutra that was limited to North America. All other terms of the agreement remain confidential.

Francois-Karl Brouillette, vice-president, scientific affairs, of Neptune, stated: "Increasing the bioavailability and absorption of EPA and DHA in a natural way is truly amazing. MaxSimil now makes it possible for everyone, including people suffering from compromised digestive health, to properly assimilate their healthy fats. We are very proud to make this ingredient accessible worldwide. This is what Neptune and our industry are all about: improving the quality of life of consumers through healthy nutrition solutions."

Serge Brunet, president of Ingenutra, added: "I am proud of this new partnership with Neptune. I am confident that they will provide the stepping stone that will allow the benefits of MaxSimil to be recognized worldwide through Neptune's well-established and growing network."

Recently, one of Neptune's clients, Xymogen, launched the MonoPure line of omega-3 EPA plus DHA products based on Maxsimil. It is aimed at the practitioner market in the United States.

About Maxsimil

The research and development of MaxSimil were developed by a researcher at the University of Rimouski, Que. MaxSimil mimics the natural digestive process and delivers a patented predigested and absorption-ready monoglyceride-rich omega-3 fish oil. It enhances the bioavailability and absorption of omega-3 fatty acids by applying a natural and gentle enzymatic process converting them into predigested natural monoglycerides. A human pharmacokinetic study has demonstrated with statistical significance three-times-greater absorption of MaxSimil EPA and DHA when compared with a regular fish oil. Furthermore, this absorption-ready omega-3 supplement is an ideal solution for populations in certain age groups, taking medication or suffering from conditions compromising their digestion health and preventing them to properly digest healthy fats. MaxSimil is a 100-per-cent-natural fish oil with no additives.